TAF5: A Potential Drug Target and Biomarker for TATA Box Binding Protein (TBP)

Target Name: TAF5

NCBI ID: G6877

TAF5

TAF5: A Potential Drug Target and Biomarker for TATA Box Binding Protein (TBP)

TATA box binding proteins (TBP) play a crucial role in regulating gene expression and are involved in various cellular processes. TAF5, a non-coding RNA-binding protein, is a novel TBP that has been identified as a potential drug target and biomarker. In this article, we will discuss the TAF5 protein, its functions, potential drug targets, and diagnostic implications.

Structure and Function

TAF5 is a 22kDa protein that is composed of 116 amino acid residues. It has a characteristic Rossmann-fold structure that is similar to other TBP proteins. TAF5 is expressed in various tissues and cells, including liver, muscle, and heart, and its levels vary depending on the cell type and developmental stage.

TAF5 functions as a TBP by binding to TATA boxes, which are present in the genomic DNA. TAF5 has been shown to enhance the transcriptional activity of TATA boxes, leading to the expression of target genes. This increase in gene expression is mediated by the interaction between TAF5 and the TBP-associated factor (TBPF).

Potential Drug Targets

TAF5 has been identified as a potential drug target due to its unique ability to enhance the transcriptional activity of TATA boxes. Many diseases, including cancer, are caused by the aberrant regulation of gene expression, and TAF5 may be a useful target for these diseases.

One of the most promising aspects of TAF5 is its potential as a cancer therapeutic. TAF5 has been shown to enhance the transcriptional activity of genes that are involved in various cancer-related processes, including cell growth, apoptosis, and angiogenesis. Therefore, TAF5 may be a useful target for cancer treatment.

Another potential drug target for TAF5 is its role in neurodegenerative diseases. TAF5 has been shown to contribute to the pathogenesis of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, TAF5 may be a promising target for neurodegenerative diseases.

Biomarkers

TAF5 has also been identified as a potential biomarker for various diseases. The increase in gene expression that is mediated by TAF5 may be an indicator of disease severity or the progression of a disease. Therefore, TAF5 may be a useful biomarker for monitoring the effectiveness of treatments for various diseases.

Conclusion

TAF5 is a novel TBP that has been identified as a potential drug target and biomarker. Its ability to enhance the transcriptional activity of TATA boxes and its potential as a cancer and neurodegenerative disease therapeutic make it an attractive target for further research. Further studies are needed to determine the effectiveness of TAF5 as a drug and to explore its potential as a biomarker for various diseases.

Protein Name: TATA-box Binding Protein Associated Factor 5

Functions: The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473, PubMed:8758937, PubMed:8942982, PubMed:9045704). The TFIID complex structure can be divided into 3 modules TFIID-A, TFIID-B, and TFIID-C (PubMed:33795473). TAF5 is involved in two modules of TFIID, in TFIID-A together with TAF3 and TBP, and in TFIID-B with TAF8 (PubMed:33795473). Involved in contacts between TFIID and TFIIF in the PIC (PubMed:33795473)

The "TAF5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets